Dose-escalation phase I studies of AVE9633, an anti CD33 antibody- maytansinoid conjugate, administered as a single agent by intravenous infusion to adult patients with relapsed or refractory CD33-positive acute myeloid leukemia.

Francis Joseph Giles

Dose-escalation phase I studies of AVE9633, an anti CD33 antibody- maytansinoid conjugate, administered as a single agent by intravenous infusion to adult patients with relapsed or refractory CD33-positive acute myeloid leukemia.

Francis Joseph Giles

Medicine

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

Original language	English (Ireland)
Journal	Investigational new drugs
Publication status	Published - 1 Jan 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Lapusan, S., Vidriales, M.B., Thomas, X., de Botton, S., Vekhoff, A., Tang, R., Dumontet, C., Morariu-Zamfir, R., Lambert, J.M., Ozoux, M.L., Poncelet, P., San Miguel, J.F ., Legrand, O., De Angelo, D., Giles, F.J. , Marie, J.P

Cite this

@article{f50647a8e4a94693927239ecf0ee0388,

title = "Dose-escalation phase I studies of AVE9633, an anti CD33 antibody- maytansinoid conjugate, administered as a single agent by intravenous infusion to adult patients with relapsed or refractory CD33-positive acute myeloid leukemia.",

author = "Giles, \{Francis Joseph\}",

year = "2011",

month = jan,

day = "1",

language = "English (Ireland)",

journal = "Investigational new drugs",

}

Dose-escalation phase I studies of AVE9633, an anti CD33 antibody- maytansinoid conjugate, administered as a single agent by intravenous infusion to adult patients with relapsed or refractory CD33-positive acute myeloid leukemia. / Giles, Francis Joseph.
In: Investigational new drugs, 01.01.2011.

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

TY - JOUR

T1 - Dose-escalation phase I studies of AVE9633, an anti CD33 antibody- maytansinoid conjugate, administered as a single agent by intravenous infusion to adult patients with relapsed or refractory CD33-positive acute myeloid leukemia.

AU - Giles, Francis Joseph

PY - 2011/1/1

Y1 - 2011/1/1

M3 - Article

JO - Investigational new drugs

JF - Investigational new drugs

ER -